Literature DB >> 9640410

Clinical profile of primary hyperparathyroidism in adolescents and young adults.

K C Loh1, Q Y Duh, D Shoback, L Gee, A Siperstein, O H Clark.   

Abstract

OBJECTIVE: Primary hyperparathyroidism (PHPT) is an uncommonly diagnosed condition among adolescents and young adults. We review the clinical characteristics of these patients based on our institutional experience.
SUBJECTS: Patients aged 12-28 years treated for PHPT at our institution from 1990 to 1996 were evaluated by a review of medical records and current follow-up data. This consisted of 22 patients (8M:14F), constituting approximately 3% of all patients operated for PHPT during this period. MEASUREMENTS: Serum and urinary calcium concentrations, renal function, and serum intact parathyroid hormone (IPTH) levels were measured in all patients. After biochemical confirmation of diagnosis, the patients completed a questionnaire to evaluate the presence of symptoms and/or conditions associated with PHPT. All the patients underwent parathyroidectomy and their tumour characteristics were evaluated. Surgical outcome was determined by measurements of serum calcium and IPTH levels postoperatively and during long-term follow-up.
RESULTS: A third of the patients were diagnosed by routine serum chemistry whereas two-thirds presented with symptoms or conditions associated with hypercalcaemia. Non-specific complaints such as fatigue or exhaustion, and weakness or lethargy constitute the most common findings on questionnaire review. A family history of PHPT was present in only 2 patients. The preoperative peak serum calcium levels ranged from 2.67 to 4.19 mmol/l (norm: 2.10-2.54 mmol/l), with a median of 3.07 mmol/l. Surgical pathologies revealed 59% solitary adenoma, 27% hyperplasia, 9% multiple adenomas and 5% carcinoma. Comparison between the adolescents (aged 12-18 years) and young adults (aged 19-28 years) revealed no differences in the clinical, pathological or laboratory profiles, except for a male predominance in adolescent patients. Fifteen patients had resection of one or more adenomas while 7 underwent subtotal parathyroidectomy. Six patients (27%) were reoperated cases, all received primary treatment elsewhere. All patients with benign PHPT were cured surgically, with a median follow-up of 47 months (range 3-77 months). One reoperated patient developed permanent hypocalcaemia. One patient with carcinoma underwent several operations for recurrence; he is now eucalcaemic despite persistent disease at 80 months from diagnosis.
CONCLUSIONS: We found a high incidence of multiglandular disease and relatively non-specific symptomatology in our adolescent and young adult patients with primary hyperparathyroidism. In view of the heterogeneous clinical expression noted in young patients, one should consider primary hyperparathyroidism in the differential diagnosis of unexplained non-specific complaints, and perform serum calcium estimations more readily in these subjects. Our experience suggests that primary hyperparathyroidism can be a serious disease with significant morbidity if left untreated, whereas parathyroidectomy provides successful results.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9640410     DOI: 10.1046/j.1365-2265.1998.00329.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  15 in total

1.  The changing pattern of diagnosing primary hyperparathyroidism in young patients.

Authors:  Irene Lou; David F Schneider; Rebecca S Sippel; Herbert Chen; Dawn M Elfenbein
Journal:  Am J Surg       Date:  2016-06-14       Impact factor: 2.565

2.  Role for limited neck exploration in young adults with apparently sporadic primary hyperparathyroidism.

Authors:  Laura A Adam; Brian J Smith; Daniel Calva-Cerqueira; James R Howe; Geeta Lal
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

Review 3.  A meta-analysis comparing the biochemistry of primary hyperparathyroidism in youths to the biochemistry of primary hyperparathyroidism in adults.

Authors:  Jeffrey Roizen; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

4.  Clinical profile of juvenile primary hyperparathyroidism: a prospective study.

Authors:  Federica Saponaro; Claudio Marcocci; Federica Cacciatore; Mario Miccoli; Elena Pardi; Simona Borsari; Gabriele Materazzi; Paolo Miccoli; Filomena Cetani
Journal:  Endocrine       Date:  2017-05-20       Impact factor: 3.633

5.  Outcomes of minimally invasive parathyroidectomy in pediatric patients with primary hyperparathyroidism owing to parathyroid adenoma: A single institution experience.

Authors:  Edna E Mancilla; Michael A Levine; N Scott Adzick
Journal:  J Pediatr Surg       Date:  2016-02-04       Impact factor: 2.545

6.  Primary hyperparathyroidism with low intact PTH levels in a 14-year-old girl.

Authors:  Amanda D Benaderet; Amy M Burton; Roderick Clifton-Bligh; Ambika P Ashraf
Journal:  J Clin Endocrinol Metab       Date:  2011-05-18       Impact factor: 5.958

7.  Primary hyperparathyroidism in the young age group: particularities of diagnostic and therapeutic schemes.

Authors:  Kenko Cupisti; Andreas Raffel; Cornelia Dotzenrath; Markus Krausch; Hans-Dietrich Röher; Klaus-Martin Schulte
Journal:  World J Surg       Date:  2004-11       Impact factor: 3.352

8.  Hungry bone syndrome after parathyroidectomy caused by an ectopic parathyroid adenoma.

Authors:  Ediz Yeşilkaya; Peyami Cinaz; Aysun Bideci; Orhun Camurdan; Fatma Demirel; Sedat Demircan
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

9.  Does multiple gland disease in primary hyperparathyroidism correlate with age or sex?

Authors:  Denis Wirowski; Bernhard J Lammers; Peter Pohl; Katharina Schwarz; Peter E Goretzki
Journal:  Langenbecks Arch Surg       Date:  2009-06-17       Impact factor: 3.445

Review 10.  Primary hyperparathyroidism in children and adolescents.

Authors:  Jeffrey Roizen; Michael A Levine
Journal:  J Chin Med Assoc       Date:  2012-08-21       Impact factor: 2.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.